This HTML5 document contains 140 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-shhttp://sh.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
dbpedia-huhttp://hu.dbpedia.org/resource/
n25https://global.dbpedia.org/id/
umbel-rchttp://umbel.org/umbel/rc/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n21http://adisinsight.springer.com/drugs/
n13http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
dbpedia-srhttp://sr.dbpedia.org/resource/
freebasehttp://rdf.freebase.com/ns/
dbpedia-pthttp://pt.dbpedia.org/resource/
dbpedia-fahttp://fa.dbpedia.org/resource/
n19http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
dbpedia-vihttp://vi.dbpedia.org/resource/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/
dbpedia-jahttp://ja.dbpedia.org/resource/

Statements

Subject Item
dbr:Gepirone
rdf:type
umbel-rc:DrugProduct yago:Vermifuge104528630 yago:Medicine103740161 yago:DrugOfAbuse103248958 dbo:ChemicalSubstance yago:Drug103247620 n13:ChemicalObject yago:MinorTranquilizer103771443 yago:PhysicalEntity100001930 yago:PsychotropicAgent104017429 yago:Substance100020090 owl:Thing yago:WikicatPiperazines yago:Agent114778436 dbo:Drug yago:Matter100020827 yago:Piperazine103946814 yago:CausalAgent100007347 wikidata:Q8386 yago:Sedative104166553 yago:WikicatAnxiolytics yago:Sedative-hypnotic104166841 yago:Tranquilizer104470232
rdfs:label
Gepirona Gepirone ゲピロン
rdfs:comment
Gepirone is an antidepressant and anxiolytic drug of the azapirone group that was synthesized by Bristol-Myers Squibb in 1986 and has been under development for the treatment of depression but has yet to be marketed. It has been under development in the U.S. in an extended release form (referred to as gepirone ER), but despite completing phase III clinical trials and demonstrating efficacy, it has been rejected multiple times by the Food and Drug Administration (FDA) during the drug approval process. However, in March 2016, the FDA reversed course and ruled favorably on the efficacy of gepirone. ゲピロン(Gepirone)は、系の抗うつ薬、抗不安薬である。アザピロン系の他の薬剤と比べ、5-HT1A受容体の選択的パーシャルアゴニストとして作用する。アメリカ合衆国で開発されたが、第三相の臨床試験をクリアできず、承認されなかった。その結果、商標名まで決まっていたものの、ゲピロンは市場には出されなかった。 ゲピロンは、ブリストル・マイヤーズ スクイブが開発したが、1993年にFabre-Kramerにライセンスされた。アメリカ食品医薬品局(FDA)はゲピロンの承認を2004年に拒絶した。2007年5月には、FDAが2004年に要請した追加の書類を添えて、再び事前登録の申請がなされたが、再び拒絶された。 Gepirona é um antidepressivo e ansiolítico da classe das azapironas. Foi sintetizado por Bristol-Myers Squibb em 1986 e tem sido estudado para o tratamento da depressão, mas ainda não é comercializado. O fármaco está em desenvolvimento nos EUA em uma forma de liberação prolongada, mas apesar de completar os ensaios clínicos de fase III e demonstrar eficácia, foi rejeitado várias vezes pela Food and Drug Administration (FDA). No entanto, em março de 2016, o FDA posicionou-se favoravelmente sobre a eficácia da gepirona.
foaf:depiction
n19:Gepirone.svg
dcterms:subject
dbc:Alpha-2_blockers dbc:Experimental_drugs dbc:Azapirones dbc:Glutarimides dbc:Aminopyrimidines dbc:Anxiolytics dbc:Antidepressants dbc:5-HT1A_agonists dbc:Piperazines dbc:Piperidines
dbo:wikiPageID
11584979
dbo:wikiPageRevisionID
1045881563
dbo:wikiPageWikiLink
dbr:Phase_III_clinical_trials dbr:Instant_release dbr:Depression_(mood) dbr:Dosage_form dbr:Azapirone dbr:Metabolism dbr:Receptor_antagonist dbr:Anxiolytic dbr:D2_receptor dbr:Binding_selectivity dbc:Alpha-2_blockers dbr:Efficacy dbr:Time_Release_Technology_(medicine) dbc:Glutarimides dbr:Partial_agonist dbr:Alpha-2_adrenergic_receptor dbc:Experimental_drugs dbc:Azapirones dbr:Drug_development dbr:Food_and_Drug_Administration dbc:Aminopyrimidines dbr:Buspirone dbr:5-HT1A_receptor dbr:Antidepressant dbr:1-(2-pyrimidinyl)piperazine dbr:Bristol-Myers_Squibb dbr:Drug dbr:Clinical_trial dbr:Potency_(pharmacology) dbr:Affinity_(pharmacology) dbc:Anxiolytics dbc:Antidepressants dbr:Fabre-Kramer dbr:List_of_investigational_antidepressants dbc:Piperazines dbr:Oral_administration dbc:Piperidines dbr:Sexual_dysfunction dbc:5-HT1A_agonists dbr:Intrinsic_activity
dbo:wikiPageExternalLink
n21:800000684
owl:sameAs
dbpedia-fa:ژپیرون dbpedia-vi:Gepirone freebase:m.02rk6dh yago-res:Gepirone dbpedia-hu:Gepiron wikidata:Q2650256 dbpedia-sh:Gepiron n25:2VFnR dbpedia-pt:Gepirona dbpedia-sr:Gepiron dbpedia-ja:ゲピロン
dbp:usan
gepirone hydrochloride
dbp:wikiPageUsesTemplate
dbt:Fdacite dbt:Stdinchicite dbt:Adrenergic_receptor_modulators dbt:Ebicite dbt:Reflist dbt:Short_description dbt:Chemspidercite dbt:Cascite dbt:Serotonin_receptor_modulators dbt:Antidepressants dbt:Anxiolytics dbt:Drugbox
dbo:thumbnail
n19:Gepirone.svg?width=300
dbp:atcSuffix
AX19
dbp:atcPrefix
N06
dbp:c
19
dbp:casNumber
83928
dbp:chembl
284092
dbp:chemspiderid
49836
dbp:eliminationHalfLife
-10800.0
dbp:h
29
dbp:iupacName
44
dbp:n
5
dbp:o
2
dbp:pubchem
55191
dbp:routesOfAdministration
dbr:Oral_administration
dbp:smiles
O=C1NCCCCN3CCNCC3
dbp:stdinchi
1
dbp:stdinchikey
QOIGKGMMAGJZNZ-UHFFFAOYSA-N
dbp:synonyms
BMY-13805, MJ-13805, ORG-13011; Ariza, Variza, Velexity
dbp:unii
JW5Y7B8Z18
dbp:verifiedrevid
437181944
dbp:watchedfields
changed
dbp:width
250
dbo:abstract
ゲピロン(Gepirone)は、系の抗うつ薬、抗不安薬である。アザピロン系の他の薬剤と比べ、5-HT1A受容体の選択的パーシャルアゴニストとして作用する。アメリカ合衆国で開発されたが、第三相の臨床試験をクリアできず、承認されなかった。その結果、商標名まで決まっていたものの、ゲピロンは市場には出されなかった。 ゲピロンは、ブリストル・マイヤーズ スクイブが開発したが、1993年にFabre-Kramerにライセンスされた。アメリカ食品医薬品局(FDA)はゲピロンの承認を2004年に拒絶した。2007年5月には、FDAが2004年に要請した追加の書類を添えて、再び事前登録の申請がなされたが、再び拒絶された。 Gepirona é um antidepressivo e ansiolítico da classe das azapironas. Foi sintetizado por Bristol-Myers Squibb em 1986 e tem sido estudado para o tratamento da depressão, mas ainda não é comercializado. O fármaco está em desenvolvimento nos EUA em uma forma de liberação prolongada, mas apesar de completar os ensaios clínicos de fase III e demonstrar eficácia, foi rejeitado várias vezes pela Food and Drug Administration (FDA). No entanto, em março de 2016, o FDA posicionou-se favoravelmente sobre a eficácia da gepirona. Além de suas propriedades antidepressivas e ansiolíticas, constatou-se que a gepirona melhora os sintomas de disfunção sexual em homens e mulheres. Os efeitos pró-sexuais parecem ser independentes de seus efeitos antidepressivos e ansiolíticos. Gepirone is an antidepressant and anxiolytic drug of the azapirone group that was synthesized by Bristol-Myers Squibb in 1986 and has been under development for the treatment of depression but has yet to be marketed. It has been under development in the U.S. in an extended release form (referred to as gepirone ER), but despite completing phase III clinical trials and demonstrating efficacy, it has been rejected multiple times by the Food and Drug Administration (FDA) during the drug approval process. However, in March 2016, the FDA reversed course and ruled favorably on the efficacy of gepirone. In addition to its antidepressant and anxiolytic properties, gepirone has been found to improve symptoms of sexual dysfunction in men and women. Moreover, the pro-sexual effects appear to be independent of its antidepressant and anxiolytic effects.
gold:hypernym
dbr:Antidepressant
prov:wasDerivedFrom
wikipedia-en:Gepirone?oldid=1045881563&ns=0
dbo:wikiPageLength
7372
dbo:casNumber
83928-76-1
dbo:chEMBL
284092
dbo:fdaUniiCode
JW5Y7B8Z18
dbo:pubchem
55191
foaf:isPrimaryTopicOf
wikipedia-en:Gepirone